An intradermal plasmid DNA cancer vaccine encoding Th1-biased polyepitopes from CDH3 (P-cadherin), CD105 (endoglin), YB-1, MDM2, and SOX2 to induce antigen-specific CD8+ cytotoxic T cells and Th1 CD4+ responses against NSCLC.
Intradermal plasmid DNA vaccine encoding Th1-biased polyepitopes from CDH3, CD105, YB-1, MDM2, and SOX2 is taken up by antigen-presenting cells, leading to in situ expression, processing, and MHC I/II presentation. This primes antigen-specific CD8+ cytotoxic T cells and Th1 CD4+ helper responses to recognize and kill NSCLC cells expressing these antigens, enhancing tumor-specific cellular immunity.
YES
INDIRECT
The DNA vaccine primes SOX2-specific CD8+ T cells via APC MHC I/II presentation. Activated CTLs recognize SOX2-derived peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated apoptosis (and Fas–FasL).
Autologous T cells retrovirally transduced to express a glypican-3 (GPC3)–specific chimeric antigen receptor, engineered to provide autocrine IL-15 and IL-21 signaling and to include an inducible caspase-9 (iCasp9) safety switch.
Autologous T cells are engineered to express a glypican-3 (GPC3)-specific chimeric antigen receptor that recognizes GPC3 on tumor cells and activates T-cell cytotoxicity; co-expression of IL-15 and IL-21 provides autocrine signaling to enhance proliferation, survival, and persistence; an inducible caspase-9 (iCasp9) safety switch enables rapid elimination of the cells upon administration of a dimerizer drug.
YES
DIRECT
GPC3-specific CAR T cells bind GPC3 on target cells and induce T-cell–mediated killing via perforin/granzyme-mediated apoptosis (with possible Fas/FasL contribution).
Autologous T cells retrovirally transduced to express a glypican-3 (GPC3)–specific chimeric antigen receptor, engineered to provide autocrine IL-15 and IL-21 signaling and to include an inducible caspase-9 (iCasp9) safety switch.
Autologous T cells are engineered to express a glypican-3 (GPC3)-specific chimeric antigen receptor that recognizes GPC3 on tumor cells and activates T-cell cytotoxicity; co-expression of IL-15 and IL-21 provides autocrine signaling to enhance proliferation, survival, and persistence; an inducible caspase-9 (iCasp9) safety switch enables rapid elimination of the cells upon administration of a dimerizer drug.
NO
INDIRECT
IL-21 receptor–expressing cells are not targeted for killing; IL-21 provides autocrine/paracrine signaling to the CAR T cells. Cytotoxicity is directed against GPC3+ cells via CAR-mediated recognition and T-cell perforin/granzyme (and Fas/FasL) killing.
Long-acting LS-engineered human IgG1 broadly neutralizing monoclonal antibody targeting the HIV-1 gp120 CD4-binding site to block attachment/entry; extended half-life via enhanced FcRn binding and may mediate Fc-effector functions (e.g., ADCC/ADCP).
Long-acting LS-engineered human IgG1 broadly neutralizing monoclonal antibody that binds the HIV-1 gp120 CD4-binding site, blocking attachment to CD4 and preventing viral entry; LS Fc modifications enhance FcRn binding to extend half-life and may enable Fc-mediated effector functions (e.g., ADCC/ADCP) against Env-expressing cells.
YES
DIRECT
Antibody binds gp120 on Env-expressing (HIV‑infected) cells and engages Fcγ receptors on effector cells to trigger ADCC/ADCP (± complement), leading to killing of the target cells.
Autologous T cells retrovirally transduced to express a glypican-3 (GPC3)–specific chimeric antigen receptor, engineered to provide autocrine IL-15 and IL-21 signaling and to include an inducible caspase-9 (iCasp9) safety switch.
Autologous T cells are engineered to express a glypican-3 (GPC3)-specific chimeric antigen receptor that recognizes GPC3 on tumor cells and activates T-cell cytotoxicity; co-expression of IL-15 and IL-21 provides autocrine signaling to enhance proliferation, survival, and persistence; an inducible caspase-9 (iCasp9) safety switch enables rapid elimination of the cells upon administration of a dimerizer drug.
NO
INDIRECT
This CAR T product targets GPC3; cells are killed when they express GPC3 via T‑cell cytotoxicity (perforin/granzyme, Fas–FasL). IL‑2R common gamma chain (CD132) is only used for IL‑15/IL‑21 signaling in the CAR T cells and is not a cytotoxic target.